Skip to content

A randomized, controlled trial of Chinese medicine compound intestinal Jiling granels in the treatment of IBS-D with 'spleen deficiency zhen'

Study on the syndrome evolution law of liver stagnation spleen deficiency of IBS-D based on gene polymorphism of neurotransmitters related to brain gut axis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012400
Enrollment
Unknown
Registered
2017-08-17
Start date
2017-08-21
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Interventions

intervention group:Chinese medicine compound intestinal Jiling particle
control group:placebo

Sponsors

Second Affiliated Hospital of Guangzhou University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Western medicine diagnostic criteria for IBS with diarrhea-predominant type belong to and comply with TCM liver spleen or weakness of the spleen stomach or stagnation of QI due to depression of the liver Permit, IBS with constipation-predominant type may be included in test cases in line; (2) Informed consent; (3) male or female patient between 18 to 65 years old.

Exclusion criteria

Exclusion criteria: 1. pregnancy, nursing mothers, or planning a pregnancy; 2. intestinal organic disease, such as inflammatory bowel disease, intestinal tuberculosis, colon polyps; 3. severe cardiovascular system, liver, kidney, hematopoietic system diseases and tumors of patients; 4. Gastrointestinal surgery record reports; 5. severe primary disease and mental illness; 6. There are drug and food allergies or allergies during the test; 7. Not signed informed consent; 8. It does not meet the inclusion criteria, according to the specified medication, can not determine the efficacy or incomplete information and other factors determine the efficacy or safety of persons; 9. researchers believe that clinical trials are not suitable for this study.

Design outcomes

Primary

MeasureTime frame
IBS symptom severity improvement;Action to Improve the quality of life of patients;Defecation symptoms, abdominal pain, abdominal distension ;Before and after the treatment Hamilton Anxiety Scale;detecting of gene polymorphism of neurotransmitters related to brain gut axis;

Countries

China

Contacts

Public ContactHuang Shaogang

Second Affiliated Hospital of Guangzhou University of TCM

huangshaogang@126.com+86 13926451320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026